|
Molecular stratification of endometrioid ovarian carcinomas. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Canon Medical Research Europa Ltd; Canon Medical Research Europa Ltd (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Tesaro |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Cor2Ed; Medscape; Tesaro |
Consulting or Advisory Role - AstraZeneca; Cor2Ed; Foundation One Inc (Inst); Nucana (Inst); Roche (Inst); Sierra Oncology; Tesaro (Inst) |
Research Funding - Aprea AB (Inst); AstraZeneca (Inst); Novartis (Inst); Nucana (Inst); Tesaro (Inst) |
Patents, Royalties, Other Intellectual Property - One patent issued and four pending for a gene expression signature to predict cancer sensitivity to anti-angiogenic therapy. (Inst) |
|
|
No Relationships to Disclose |